Chengdu Institute of Biological Products Co., Ltd.: Pentavalent Diphtheria, Pertussis, Tetanus, and Haemophilus influenzae type b combined vaccine enters phase I clinical trial.

On March 24th, Chifeng Biology announced that the company recently learned that the adsorbed acellular pertussis type b influenza hemophilus influenzae B combination vaccine developed by its wholly-owned subsidiary Chifeng Lvzhu has initiated Phase I clinical trials in Guangxi. Lvzhu independently developed the pentavalent vaccine composed of pertussis, diphtheria, tetanus, and Hib infections, which can reduce the number of injections and enhance compliance with preventive vaccination.